Generic Makers Fear Weakening Of Hatch-Waxman Rules

Law360, New York (July 27, 2005, 12:00 AM EDT) -- U.S. generic drug makers are wary of plans to reform the U.S. patent system, fearing that the powerful brand-name drug lobby will use the process to water down landmark legislation that paved the way for the generic pharmaceuticals industry.

The industry fears that some provisions in the bill – especially a change in the standards for inequitable conduct during the patent application process – could fundamentally alter the rules of the game to give the upper hand to drug originators in patent litigation.

“What might appear...
To view the full article, register now.